EU scrutiny procedure could affect 1 in 10 high-risk devices
This article was originally published in Clinica
Under 10% of high-risk medical devices entering the EU are likely to be subject to the new scrutiny mechanism that the European Commission has proposed. That is the estimate given by Manfred Kohler of the health technology and cosmetics unit (DG Sanco, B2) at the commission that issued the proposals last week.
You may also be interested in...
EU marketing applications from Vertex and Roche have reverted to standard review timelines at the European Medicines Agency. The outcomes of three fast-track requests that companies have made for their planned filings are still unknown.
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.
KTE-X19, Kite’s potential new CAR-T therapy, will in the end be fast-tracked at the European Medicines Agency. Lilly failed to secure the speedy review it was seeking for selpercatinib